Loading
Pharmaceutical
11 min read
Areas of Expertise :
Pharmaceutical, Cardiology, Pharmacology, Food And Drug Administration (FDA), Product Liability
Published Date:
Last Modified Date:
Jurisdiction:
New Jersey State
McDarby v. Merck & Co., Inc. arose from New Jersey Vioxx injury litigation in which plaintiff John McDarby sued Merck over alleged harms tied to Vioxx use. The published New Jersey Appellate Division decision addressed how the claims should be analyzed under New Jersey law, including the relationship between product-liability theories and Consumer Fraud Act theories, along with the standards governing proof and recovery. The case also became a focal point for later reporting and commentary because it involved a substantial damages award and continued appellate attention to what legal theories are available in prescription drug cases.
On review, the courts focused on the legal framework that governs prescription drug claims and on which remedies and statutory causes of action may proceed when the allegations center on product warnings and risk information. In that setting, the decision is frequently discussed in connection with how New Jersey courts treat consumer-fraud theories alongside the Product Liability Act, and how fraud-on-the-agency concepts intersect with preemption arguments in drug litigation, where warnings and regulatory submissions are part of the record. This pharmaceutical context is reflected in the way the sources frame the dispute around a branded prescription drug, alleged injury risk, and the legal consequences of how warnings and related information are presented and evaluated in court.
Vioxx was approved by the FDA on May 20, 1999 for specified pain and osteoarthritis-related uses, and the required labeling did not include cardiovascular warnings or precautions at that time. The approval letter noted that labeling revisions could be required if additional safety or effectiveness information emerged. This approval-and-label baseline later became central to disputes over what risk information was known, what warnings were given, and when they should have changed.
On March 21, 2000, McDarby’s family physician, Dr. John Braun, prescribed Vioxx at a 25 mg dose for osteoarthritis, and McDarby took it daily for several years. The record describes McDarby’s exposure as long-term use leading up to the later injury event. This treatment history framed the case’s causation and warning issues as a dispute about risk communication during ongoing use of an FDA-approved prescription drug.
The record describes materials provided to the FDA on January 8, 2001 in response to questions about cardiovascular outcomes in Vioxx studies. It also discusses a Merck meta-analysis referenced at trial in connection with how myocardial infarction data were presented and interpreted. In the punitive-damages phase, the dispute was framed around whether information was withheld or misrepresented in a way the plaintiffs argued was material, a theory the Appellate Division later treated as tied to regulator-focused allegations.
On September 17, 2001, Merck received an FDA warning letter stating that promotional activities and materials were “false, lacking in fair balance, or otherwise misleading” under federal law and regulations. The case record includes evidence about how cardiovascular risk information was communicated to prescribers and the public during the product’s marketing period. This event became part of the broader narrative about warning adequacy and messaging in a pharmaceutical setting where labeling and promotion can affect prescribing decisions.
The opinion identifies April 2002 as the point when the FDA approved a revised label for Vioxx, a benchmark used in analyzing warning adequacy and what information was available by then. The litigation record presented issues about whether plaintiffs overcame the presumption of adequacy connected to FDA-approved warnings. This timing also framed arguments about whether additional warnings could have been strengthened through labeling mechanisms recognized in federal regulations.
McDarby sustained a heart attack and fractured hip on April 15, 2004 at age 75, after taking Vioxx daily until that event. At trial, plaintiffs used causation testimony to connect Vioxx to the heart attack, including evidence from medical and epidemiological experts. The court later addressed whether the evidence supported the jury’s finding that Vioxx was a substantial contributing factor to the injury.
Vioxx continued to be marketed until September 30, 2004, when evidence of adverse cardiovascular events from the approved study led to Merck’s voluntary withdrawal of the drug. The decision treats this withdrawal date as an endpoint for the period in which the drug was widely prescribed and marketed. In the case narrative, it served as context for how risk information evolved while the drug remained available.
The opinion discusses an FDA memorandum dated April 6, 2005 concerning cardiovascular risks of other NSAIDs and notes that the trial judge excluded it under an evidentiary balancing analysis. On appeal, Merck argued that the memorandum should have been admitted because it contested key scientific propositions in plaintiffs’ case. The appellate court addressed the evidentiary dispute as part of its review of whether trial rulings warranted reversal.
The consolidated appeals were argued on January 16, 2008, with Merck challenging multiple aspects of the trial outcomes, including statutory theories and damages components. The case posture at this stage involved a $15.7 million judgment in the McDarby matter and a $2.27 million judgment in the Cona matter, with the latter heavily driven by attorneys’ fees and costs. The appellate review focused on what claims could legally proceed under New Jersey statutes and what portions of the trial result could stand.
On May 29, 2008, the Appellate Division affirmed the compensatory damages award to McDarby on the failure-to-warn claim under the Product Liability Act, finding the claim not preempted and finding no reversible error on that compensatory recovery. The court reversed the punitive damages award as preempted under federal law principles applied to the fraud-on-the-FDA theory, and it also reversed the damages and attorneys’ fees awards under the Consumer Fraud Act for both McDarby and Cona, concluding those CFA claims were subsumed within the PLA. As stated in the decision’s summary, the net result was that compensatory damages under the PLA remained, while punitive damages and the CFA-based relief were set aside.
A later disposition reflects that the New Jersey Supreme Court dismissed certification as improvidently granted in 2009 (reported at 200 N.J. 267 (2009)), ending further review in that track. As a result, the Appellate Division’s May 29, 2008 published decision remained the controlling appellate resolution, affirming compensatory recovery under the Product Liability Act while leaving in place the reversal of punitive damages and Consumer Fraud Act-based awards and fee relief.
Court:
Superior Court of New Jersey, Law Division, Atlantic County
Case Name:
McDarby v. Merck & Co., Inc.
Pharmaceutical Product Liability
Drug Labels
FDA Regulation
Drug Regulation
Cardiovascular medicine
Heart disease
Consumer Fraud
Safety Warnings
Regulatory Issues
McDarby v. Merck & Co., Inc. arose from New Jersey Vioxx injury litigation in which plaintiff John McDarby sued Merck over alleged harms tied to Vioxx use. The published New Jersey Appellate Division decision addressed how the claims should be analyzed under New Jersey law, including the relationship between product-liability theories and Consumer Fraud Act theories, along with the standards governing proof and recovery. The case also became a focal point for later reporting and commentary because it involved a substantial damages award and continued appellate attention to what legal theories are available in prescription drug cases.
On review, the courts focused on the legal framework that governs prescription drug claims and on which remedies and statutory causes of action may proceed when the allegations center on product warnings and risk information. In that setting, the decision is frequently discussed in connection with how New Jersey courts treat consumer-fraud theories alongside the Product Liability Act, and how fraud-on-the-agency concepts intersect with preemption arguments in drug litigation, where warnings and regulatory submissions are part of the record. This pharmaceutical context is reflected in the way the sources frame the dispute around a branded prescription drug, alleged injury risk, and the legal consequences of how warnings and related information are presented and evaluated in court.
Vioxx was approved by the FDA on May 20, 1999 for specified pain and osteoarthritis-related uses, and the required labeling did not include cardiovascular warnings or precautions at that time. The approval letter noted that labeling revisions could be required if additional safety or effectiveness information emerged. This approval-and-label baseline later became central to disputes over what risk information was known, what warnings were given, and when they should have changed.
On March 21, 2000, McDarby’s family physician, Dr. John Braun, prescribed Vioxx at a 25 mg dose for osteoarthritis, and McDarby took it daily for several years. The record describes McDarby’s exposure as long-term use leading up to the later injury event. This treatment history framed the case’s causation and warning issues as a dispute about risk communication during ongoing use of an FDA-approved prescription drug.
The record describes materials provided to the FDA on January 8, 2001 in response to questions about cardiovascular outcomes in Vioxx studies. It also discusses a Merck meta-analysis referenced at trial in connection with how myocardial infarction data were presented and interpreted. In the punitive-damages phase, the dispute was framed around whether information was withheld or misrepresented in a way the plaintiffs argued was material, a theory the Appellate Division later treated as tied to regulator-focused allegations.
On September 17, 2001, Merck received an FDA warning letter stating that promotional activities and materials were “false, lacking in fair balance, or otherwise misleading” under federal law and regulations. The case record includes evidence about how cardiovascular risk information was communicated to prescribers and the public during the product’s marketing period. This event became part of the broader narrative about warning adequacy and messaging in a pharmaceutical setting where labeling and promotion can affect prescribing decisions.
The opinion identifies April 2002 as the point when the FDA approved a revised label for Vioxx, a benchmark used in analyzing warning adequacy and what information was available by then. The litigation record presented issues about whether plaintiffs overcame the presumption of adequacy connected to FDA-approved warnings. This timing also framed arguments about whether additional warnings could have been strengthened through labeling mechanisms recognized in federal regulations.
McDarby sustained a heart attack and fractured hip on April 15, 2004 at age 75, after taking Vioxx daily until that event. At trial, plaintiffs used causation testimony to connect Vioxx to the heart attack, including evidence from medical and epidemiological experts. The court later addressed whether the evidence supported the jury’s finding that Vioxx was a substantial contributing factor to the injury.
Vioxx continued to be marketed until September 30, 2004, when evidence of adverse cardiovascular events from the approved study led to Merck’s voluntary withdrawal of the drug. The decision treats this withdrawal date as an endpoint for the period in which the drug was widely prescribed and marketed. In the case narrative, it served as context for how risk information evolved while the drug remained available.
The opinion discusses an FDA memorandum dated April 6, 2005 concerning cardiovascular risks of other NSAIDs and notes that the trial judge excluded it under an evidentiary balancing analysis. On appeal, Merck argued that the memorandum should have been admitted because it contested key scientific propositions in plaintiffs’ case. The appellate court addressed the evidentiary dispute as part of its review of whether trial rulings warranted reversal.
The consolidated appeals were argued on January 16, 2008, with Merck challenging multiple aspects of the trial outcomes, including statutory theories and damages components. The case posture at this stage involved a $15.7 million judgment in the McDarby matter and a $2.27 million judgment in the Cona matter, with the latter heavily driven by attorneys’ fees and costs. The appellate review focused on what claims could legally proceed under New Jersey statutes and what portions of the trial result could stand.
On May 29, 2008, the Appellate Division affirmed the compensatory damages award to McDarby on the failure-to-warn claim under the Product Liability Act, finding the claim not preempted and finding no reversible error on that compensatory recovery. The court reversed the punitive damages award as preempted under federal law principles applied to the fraud-on-the-FDA theory, and it also reversed the damages and attorneys’ fees awards under the Consumer Fraud Act for both McDarby and Cona, concluding those CFA claims were subsumed within the PLA. As stated in the decision’s summary, the net result was that compensatory damages under the PLA remained, while punitive damages and the CFA-based relief were set aside.
A later disposition reflects that the New Jersey Supreme Court dismissed certification as improvidently granted in 2009 (reported at 200 N.J. 267 (2009)), ending further review in that track. As a result, the Appellate Division’s May 29, 2008 published decision remained the controlling appellate resolution, affirming compensatory recovery under the Product Liability Act while leaving in place the reversal of punitive damages and Consumer Fraud Act-based awards and fee relief.
Plaintiff: The appellate opinion identifies Dr. Harlan Krumholz (described as a cardiologist and epidemiologist) and Dr. Nicholas DePace (described as a cardiologist) as plaintiff witnesses, and summarizes their testimony as addressing cardiovascular-risk evidence and medical-causation issues based on the trial record, including McDarby’s medical history and the studies and data discussed at trial. Their opinions were presented to support the jury’s causation determination on the compensatory failure-to-warn claim, rather than as definitive proof of causation.
Defense: The opinion identifies Dr. Barry Rayburn as a Merck cardiology expert. The appellate court recounts that his testimony and cross-examination addressed points relevant to Merck’s causation defense, including discussion of exposure and risk-related figures referenced in the trial evidence, as part of Merck’s effort to dispute plaintiffs’ causation theory.
Merck identified Lisa Rarick, M.D. as its regulatory expert and the trial judge ruled on the permissible scope of her testimony. The opinion states the court allowed testimony about FDA new-drug application requirements, how the FDA reviews applications, and post-market safety evaluation concepts, including rebuttal to testimony suggesting the FDA was dysfunctional. The opinion also states Merck ultimately did not call her as a witness in the compensatory-damages phase, even though the court ruled on what she could address.
This type of expert is often engaged in cases involving FDA-approved prescription drugs to explain how labeling, risk language, and safety communications are developed over time. They commonly review label history, safety-signal discussions, and the timing of warnings to help the factfinder understand what information was available and how it was communicated. In cases centered on warnings and risk evidence, they are often asked to provide context on the regulatory and scientific record without offering legal conclusions.
The decision treated the Product Liability Act as the primary framework for injury claims tied to warnings and risk information for a prescription drug. Early motion practice and trial framing should reflect that structure to reduce theory sprawl and appellate vulnerability. Align pleadings, jury charges, and proof with the PLA elements the court applied.
The court reversed Consumer Fraud Act-based relief and related fee awards where the alleged conduct and harm tracked a product-injury warning theory. Defense counsel can use this to narrow the case and challenge CFA theories that duplicate PLA concepts. Plaintiff counsel should stress-test whether any CFA theory truly stands apart from the PLA injury claim as framed in the record.
The decision addressed punitive-damages theory tied to alleged misrepresentation or withholding of information from the FDA and treated that pathway as legally constrained in this context. When the evidence involves labeling history and regulatory communications, counsel should expect close scrutiny of arguments about what a regulator would have done under different inputs. In a pharmaceutical record focused on warnings and safety data, durable trial themes tend to stay anchored to the warning and causation proof the jury can evaluate.
The opinion shows how trial-level rulings on what evidence comes in or is limited, can become central on appeal. Preserve objections and offers of proof in a way that clearly ties the evidence to warning adequacy, causation, or statutory presumptions discussed in the case. This is especially important when parties dispute timing and content of warning changes over the life of the drug.
The appellate court evaluated whether the trial record supported the jury’s compensatory verdict, which places a premium on disciplined expert proof. Connect opinions to the plaintiff’s medical history, exposure timeline, and the risk evidence actually admitted, while avoiding overreach beyond what the record supports. In pharmaceutical product litigation, careful wording and method transparency can affect whether a verdict is sustained.
The McDarby v. Merck (Vioxx) litigation remains a key New Jersey prescription-drug injury decision because it clarified how the Product Liability Act governs personal-injury claims tied to warnings and risk information, and it narrowed when parallel statutory theories may proceed. The Appellate Division’s disposition left the compensatory verdict in place under the Product Liability Act while rejecting Consumer Fraud Act-based relief and setting aside punitive-damages relief tied to the theory presented. For attorneys, the case reinforces the value of disciplined claim selection, careful jury-charge framing, and a trial record that stays tightly connected to the legal elements the reviewing court will apply.
More broadly, the case shows how warning adequacy disputes can turn on the timing and content of labeling, the role of risk evidence offered at trial, and how courts treat arguments linked to communications with the FDA. In this pharmaceutical context, the record’s focus on FDA-approved labeling benchmarks, post-market safety evaluation concepts, and contested interpretations of cardiovascular risk data provides a roadmap for litigators managing evidence and theory selection. The outcome also signals that appellate review may preserve core compensatory recovery while limiting remedies that depend on statutory overlap or on theories the court treats as legally constrained in this setting.
What was McDarby v. Merck (Vioxx) about in New Jersey?
McDarby v. Merck arose from claims that Vioxx use contributed to a heart attack and that the drug’s warnings and risk information were inadequate under New Jersey law. The dispute moved through trial and appellate review focused on what legal theories and remedies could stand. It is often referenced in New Jersey prescription-drug injury litigation because it addresses warning-based liability and appellate limits on certain forms of relief.
What did the New Jersey Appellate Division decide in the published 2008 opinion?
The Appellate Division affirmed compensatory recovery for McDarby on a failure-to-warn claim under the New Jersey Product Liability Act. It reversed Consumer Fraud Act-based relief and related fee awards described in the record, and it also reversed punitive-damages relief tied to the theory presented. The result preserved compensatory damages while narrowing other recovery categories.
Why did the court reject Consumer Fraud Act recovery in McDarby and Cona?
The Appellate Division concluded the Consumer Fraud Act theories, as presented, were subsumed within the Product Liability Act framework governing product-injury claims based on warnings and risk information. Because of that overlap, the court set aside the CFA-based awards, including fee components discussed in the opinion. This is often used by counsel to evaluate early whether a CFA theory is likely to survive when the core dispute is warning adequacy and injury.
Why were punitive damages set aside in McDarby?
The punitive-damages claim, as framed, depended on allegations tied to communications with the FDA, and the court treated that pathway as legally constrained in this context. The Appellate Division reversed the punitive-damages award based on its analysis of the theory presented. For litigators, this reinforces that punitive exposure may be limited when it hinges on regulator-focused allegations rather than the warning claim itself.
Plaintiff: The appellate opinion identifies Dr. Harlan Krumholz (described as a cardiologist and epidemiologist) and Dr. Nicholas DePace (described as a cardiologist) as plaintiff witnesses, and summarizes their testimony as addressing cardiovascular-risk evidence and medical-causation issues based on the trial record, including McDarby’s medical history and the studies and data discussed at trial. Their opinions were presented to support the jury’s causation determination on the compensatory failure-to-warn claim, rather than as definitive proof of causation.
Defense: The opinion identifies Dr. Barry Rayburn as a Merck cardiology expert. The appellate court recounts that his testimony and cross-examination addressed points relevant to Merck’s causation defense, including discussion of exposure and risk-related figures referenced in the trial evidence, as part of Merck’s effort to dispute plaintiffs’ causation theory.
Merck identified Lisa Rarick, M.D. as its regulatory expert and the trial judge ruled on the permissible scope of her testimony. The opinion states the court allowed testimony about FDA new-drug application requirements, how the FDA reviews applications, and post-market safety evaluation concepts, including rebuttal to testimony suggesting the FDA was dysfunctional. The opinion also states Merck ultimately did not call her as a witness in the compensatory-damages phase, even though the court ruled on what she could address.
This type of expert is often engaged in cases involving FDA-approved prescription drugs to explain how labeling, risk language, and safety communications are developed over time. They commonly review label history, safety-signal discussions, and the timing of warnings to help the factfinder understand what information was available and how it was communicated. In cases centered on warnings and risk evidence, they are often asked to provide context on the regulatory and scientific record without offering legal conclusions.
The decision treated the Product Liability Act as the primary framework for injury claims tied to warnings and risk information for a prescription drug. Early motion practice and trial framing should reflect that structure to reduce theory sprawl and appellate vulnerability. Align pleadings, jury charges, and proof with the PLA elements the court applied.
The court reversed Consumer Fraud Act-based relief and related fee awards where the alleged conduct and harm tracked a product-injury warning theory. Defense counsel can use this to narrow the case and challenge CFA theories that duplicate PLA concepts. Plaintiff counsel should stress-test whether any CFA theory truly stands apart from the PLA injury claim as framed in the record.
The decision addressed punitive-damages theory tied to alleged misrepresentation or withholding of information from the FDA and treated that pathway as legally constrained in this context. When the evidence involves labeling history and regulatory communications, counsel should expect close scrutiny of arguments about what a regulator would have done under different inputs. In a pharmaceutical record focused on warnings and safety data, durable trial themes tend to stay anchored to the warning and causation proof the jury can evaluate.
The opinion shows how trial-level rulings on what evidence comes in or is limited, can become central on appeal. Preserve objections and offers of proof in a way that clearly ties the evidence to warning adequacy, causation, or statutory presumptions discussed in the case. This is especially important when parties dispute timing and content of warning changes over the life of the drug.
The appellate court evaluated whether the trial record supported the jury’s compensatory verdict, which places a premium on disciplined expert proof. Connect opinions to the plaintiff’s medical history, exposure timeline, and the risk evidence actually admitted, while avoiding overreach beyond what the record supports. In pharmaceutical product litigation, careful wording and method transparency can affect whether a verdict is sustained.
The McDarby v. Merck (Vioxx) litigation remains a key New Jersey prescription-drug injury decision because it clarified how the Product Liability Act governs personal-injury claims tied to warnings and risk information, and it narrowed when parallel statutory theories may proceed. The Appellate Division’s disposition left the compensatory verdict in place under the Product Liability Act while rejecting Consumer Fraud Act-based relief and setting aside punitive-damages relief tied to the theory presented. For attorneys, the case reinforces the value of disciplined claim selection, careful jury-charge framing, and a trial record that stays tightly connected to the legal elements the reviewing court will apply.
More broadly, the case shows how warning adequacy disputes can turn on the timing and content of labeling, the role of risk evidence offered at trial, and how courts treat arguments linked to communications with the FDA. In this pharmaceutical context, the record’s focus on FDA-approved labeling benchmarks, post-market safety evaluation concepts, and contested interpretations of cardiovascular risk data provides a roadmap for litigators managing evidence and theory selection. The outcome also signals that appellate review may preserve core compensatory recovery while limiting remedies that depend on statutory overlap or on theories the court treats as legally constrained in this setting.
What was McDarby v. Merck (Vioxx) about in New Jersey?
McDarby v. Merck arose from claims that Vioxx use contributed to a heart attack and that the drug’s warnings and risk information were inadequate under New Jersey law. The dispute moved through trial and appellate review focused on what legal theories and remedies could stand. It is often referenced in New Jersey prescription-drug injury litigation because it addresses warning-based liability and appellate limits on certain forms of relief.
What did the New Jersey Appellate Division decide in the published 2008 opinion?
The Appellate Division affirmed compensatory recovery for McDarby on a failure-to-warn claim under the New Jersey Product Liability Act. It reversed Consumer Fraud Act-based relief and related fee awards described in the record, and it also reversed punitive-damages relief tied to the theory presented. The result preserved compensatory damages while narrowing other recovery categories.
Why did the court reject Consumer Fraud Act recovery in McDarby and Cona?
The Appellate Division concluded the Consumer Fraud Act theories, as presented, were subsumed within the Product Liability Act framework governing product-injury claims based on warnings and risk information. Because of that overlap, the court set aside the CFA-based awards, including fee components discussed in the opinion. This is often used by counsel to evaluate early whether a CFA theory is likely to survive when the core dispute is warning adequacy and injury.
Why were punitive damages set aside in McDarby?
The punitive-damages claim, as framed, depended on allegations tied to communications with the FDA, and the court treated that pathway as legally constrained in this context. The Appellate Division reversed the punitive-damages award based on its analysis of the theory presented. For litigators, this reinforces that punitive exposure may be limited when it hinges on regulator-focused allegations rather than the warning claim itself.
How did FDA labeling and timing factor into the warning dispute?
The record discusses FDA-approved labeling benchmarks and later label revisions as reference points in the parties’ warning arguments. It also addresses trial issues involving FDA review concepts and post-market safety context offered through evidence. In a pharmaceutical case centered on prescription-drug warnings, these timing points can affect how warning adequacy arguments are presented and evaluated.
What is the practical takeaway for New Jersey drug-injury pleadings and trial strategy?
McDarby supports keeping the case tightly organized around the Product Liability Act elements for prescription-drug warning claims. It also shows the importance of building a clean record on what risk evidence is admitted and how it connects to causation and warning adequacy. For New Jersey counsel, the decision is a reminder to pressure-test overlapping statutory theories and preserve key rulings for appeal.
Pharmaceutical Product Liability
Drug Labels
FDA Regulation
Drug Regulation
Cardiovascular medicine
Heart disease
Consumer Fraud
Safety Warnings
Regulatory Issues
Securities, +4
Pharmaceutical
Pharmaceutical, +4
Pharmaceutical
How did FDA labeling and timing factor into the warning dispute?
The record discusses FDA-approved labeling benchmarks and later label revisions as reference points in the parties’ warning arguments. It also addresses trial issues involving FDA review concepts and post-market safety context offered through evidence. In a pharmaceutical case centered on prescription-drug warnings, these timing points can affect how warning adequacy arguments are presented and evaluated.
What is the practical takeaway for New Jersey drug-injury pleadings and trial strategy?
McDarby supports keeping the case tightly organized around the Product Liability Act elements for prescription-drug warning claims. It also shows the importance of building a clean record on what risk evidence is admitted and how it connects to causation and warning adequacy. For New Jersey counsel, the decision is a reminder to pressure-test overlapping statutory theories and preserve key rulings for appeal.